Searchable abstracts of presentations at key conferences in endocrinology

ea0081p148 | Pituitary and Neuroendocrinology | ECE2022

AZP-3813, a bicyclic 16-amino acid peptide antagonist of the human growth hormone receptor as a potential new treatment for acromegaly

Milano Stephane , Kurasaki Haruaki , Tomiyama Tatsuya , Reid Patrick , Jan Van der Lely Aart , Culler Michael D.

Medical treatment of acromegaly is based on either suppressing pituitary GH secretion or inhibiting GH action by preventing interaction with its receptor in order to suppress the elevated levels of IGF1. AZP-3813 is a 16-amino acid, bicyclic peptide antagonist of the GH receptor (GHR) derived from peptide sequences discovered using a unique, cell-free in vitro transcription-translation system screened against the human GHR, and that was optimized by rational design to increase...

ea0063oc6.1 | Obesity | ECE2019

Impaired glucose homeostasis in leptin-deficient ob/ob mice is corrected by AZP-3404, a 9-amino acid peptide analog derived from insulin-like growth factor-binding protein 2, a key mediator of leptin action

Culler Michael D , Delale Thomas , Milano Stephane , van der Lely Aart Jan , Abribat Thierry , Clemmons David

The key metabolic hormone, leptin, acts in part through the liver to regulate glucose homeostasis, as well as the maturation of both adipocytes and osteoblasts. These actions have been demonstrated to be mediated by insulin-like growth factor binding protein 2 (IGFBP-2), independent of its ability to bind IGF1. The effects of IGFBP-2 on adipocyte and osteoblast maturation can be localized to a short peptide sequence within the unique heparin binding domain (HBD-1) of IGFBP-2. ...

ea0063p621 | Diabetes, Obesity and Metabolism 2 | ECE2019

Nonclinical development of livoletide (AZP-531), a peptide analog of unacylated ghrelin for the treatment of hyperphagia in Prader-Willi syndrome

Milano Stephane , Allas Soraya , Cade Didier , Briffaux Jean-Paul , Spencer Andrew

Prader-Willi syndrome (PWS) is a rare complex endocrine disease characterized by hyperphagia and abnormal food-related behaviors that contribute to severe morbidity and early mortality and to a significant burden on patients and caregivers. There are no approved treatments for hyperphagia in PWS. Patients with PWS have increased circulating levels of the orexigenic hormone acylated ghrelin (AG) with a relative deficit of unacylated ghrelin (UAG). These abnormalities in AG and ...